<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515722</url>
  </required_header>
  <id_info>
    <org_study_id>2010-05-106</org_study_id>
    <nct_id>NCT01515722</nct_id>
  </id_info>
  <brief_title>Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder</brief_title>
  <official_title>Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder : 6-month, Randomized, Open-label, Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives: To explore the effectiveness of adjunctive intervention to enhance the
      medication compliance and persistence in patients with Overactive Bladder (OAB), thereby to
      improve treatment outcomes

      Study Hypothesis: Health Education Intervention (HEI) can enhance the medication compliance
      and persistence, thereby can improve the treatment outcomes in conjunction with
      pharmacological therapy in OAB patients

      Study Design: 6-month, randomized, open-label, multi-center trial at 13 university hospitals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment - Fesoterodine (Toviaz) 4 or 8mg

      Interventions (2 arms)

      - Arm 1: No intervention

      Patients in this arm will not be given HEI in conjunction with pharmacotherapy (Toviaz) which
      was developed for this trial.

      - Arm 2: Health education intervention (HEI)

      HEI will be performed by trained study coordinators with the leaflet designed for this trial
      composed of 4 parts.

        1. Part 1: Understanding OAB Physiology of bladder Definition, symptom and prevalence of
           OAB OAB in a treatable condition. There are many options that may help your symptoms.
           Lifestyle change Medications Bladder training Pelvic floor muscle exercise

        2. Part 2: Behavioral/lifestyle modification Modification of dietary habits Limit bladder
           irritants- caffeine (coffee, tea, coke...), juice, chemical flavors, spicy food. etc.
           Altering fluid intake Weight management Learn how weight can affect their condition Stop
           smoking Constipation management

        3. Part 3: Bladder training Timed voiding- Goal is urinating every 3 or 4 hours during the
           day without fear of wetting accidents.

           Urgency suppression Pelvic muscle contraction, count backwards from 100 by 7seconds, etc
           Pelvic floor muscle exercise Contraction (fast and slow) and relax the muscle for a
           count of 3. Repeat the fast and slow contractions 10 - 15 times. Do those at least 3
           times a day.

        4. Part 4: Understanding antimuscarinics How the medicine works How to take it Tips that
           may help manage side effects- dry mouth, constipation Therapy expectations

        5. HEI include 3-day voiding diary for self tracking method.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the % of patients maintaining persistence between no intervention and HEI group</measure>
    <time_frame>6 months</time_frame>
    <description>Definition of &quot;Maintaining Persistence&quot;= a gap of ≤ 30 days between successive prescription fills</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the % of patients maintaining persistence between no intervention and HEI group</measure>
    <time_frame>1, 2 and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the % of the patients with the compliance rate ≥ 80% between no intervention and HEI group</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>Calculation of Compliance (%)= (total no. of drug prescribed - no. of remained drug)/total no. of drug prescribed x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the compliance rate between no intervention and HEI group</measure>
    <time_frame>1, 2, 4 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in OAB symptoms between no intervention and HEI group</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>OABSS OAB-q short form questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the treatment satisfaction between no intervention and HEI group</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for non-persistence</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>Definition of non-persistence = a gap of &gt; 30 days between successive prescription fills
Examples
Insufficient clinical response
Adverse event
Satisfied with treatment response
Laboratory abnormality
Subject died
Protocol violation
Lost to F/U
Subject no longer willing to participate in study
Pregnancy
High patient out-pocket cost
Others (provide detailed reason)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">692</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Health education intervention (HEI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health education intervention (HEI)</intervention_name>
    <description>&lt;Part 1&gt; Understanding OAB
&lt;Part 2&gt; Behavioral/lifestyle modification
&lt;Part 3&gt; Bladder training
&lt;Part 4&gt; Understanding antimuscarinics</description>
    <arm_group_label>Health education intervention (HEI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged ≥ 18 years with OAB symptoms for ≥ 3 months

          -  The sum score of the OABSS ≥ 3 with the score of the question no.3 (urgency) ≥ 2

          -  The sum score of the OAB V8 ≥ 8

        Exclusion Criteria:

          -  Any condition that would contraindication of anticholinergic treatment

          -  Symptomatic acute UTI during the run-in period

          -  Diagnosed or suspected interstitial cystitis

          -  Treatment with anticholinergic drugs within 12 months prior to Screening and persist
             over 3 months

          -  Treatment within the 14 days preceding Screening, or expected to initiate treatment
             during the study with any other treatment for overactive bladder.

          -  An indwelling catheter or practicing intermittent self-catheterization

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyu-Sung Lee, MD, Ph.D</last_name>
    <phone>82-2-3410-3554</phone>
    <email>ksleedr@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Bucheon</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joon Chul Kim, MD, PhD</last_name>
      <phone>82-32-340-7071</phone>
      <email>kjc@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Joon Chul Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bucheon Hospital, Soonchunhyang University College of Medicine</name>
      <address>
        <city>Bucheon</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young Ho Kim, MD, PhD</last_name>
      <phone>82-32-621-5463</phone>
      <email>yhkuro@schbc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Ho Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Changwon Hospital, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Changwon</city>
        <zip>630-522</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Suk Lee, MD, PhD</last_name>
      <phone>82-55-290-6550</phone>
      <email>ysuro.lee@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Young-Suk Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University College of Medicine</name>
      <address>
        <city>Daegu</city>
        <zip>705-034</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duk Yoon Kim, MD, PhD</last_name>
      <phone>82-53-650-4663</phone>
      <email>dykim@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Duk Yoon Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Deajeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Gil Na, MD, PhD</last_name>
      <phone>82-42-220-7778</phone>
      <email>yongna@cnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Gil Na, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Medical School</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Deuk Kwon, MD, PhD</last_name>
      <phone>82-61-379-7540</phone>
      <email>urokwon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong-Deuk Kwon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Zoo Lee, MD, PhD</last_name>
      <phone>82-51-240-7350</phone>
      <email>toohotman@pusan.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Zoo Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheil General Hospital &amp; Women's Healthcare Center, College of Medicine, Kwandong University</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ju Tae Seo, MD, PhD</last_name>
      <phone>82-2-2000-7585</phone>
      <email>jtandro@cgh.co.kr</email>
    </contact>
    <investigator>
      <last_name>Ju Tae Seo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung June Oh, MD, PhD</last_name>
      <phone>82-2-2072-2406</phone>
      <email>sjo@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung June Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jang Hwan Kim, MD, PhD</last_name>
      <phone>82-2-2228-2310</phone>
      <email>yayanada@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Jang Hwan Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Sung Lee, MD, PhD</last_name>
      <phone>82-2-3410-3554</phone>
      <email>ksleedr@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Kyu-Sung Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anam Hospital, College of Medicine, Korea University</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Gu Lee, MD, PhD</last_name>
      <phone>82-2-920-5683</phone>
      <email>jeongkl@kumc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Gu Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, Ulsan University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Soo Choo, MD, PhD</last_name>
      <phone>82-2-3010-3735</phone>
      <email>mschoo@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Myung-Soo Choo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <name_title>Kyu-Sung Lee/Professor</name_title>
    <organization>Samsung Medical Center, Sungkyunkwan University School of Medicine</organization>
  </responsible_party>
  <keyword>Medication Persistence</keyword>
  <keyword>Compliance</keyword>
  <keyword>Health Education Intervention (HEI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

